▲The medical artificial intelligence (AI) corporation Lunit announced on the 13th that it provided AI-based medical examination services to pilgrims during the Hajj, the largest Islamic religious event. The company was selected as the official medical partner for the Hajj pilgrimage period by the Saudi Arabian government and the Saudi Sehha Virtual Hospital. As a result, it supplied the chest X-ray AI image analysis solution 'Lunit Insight CXR' to support screening and timely treatment for infectious respiratory diseases such as tuberculosis. Lunit CEO Seo Beom-seok said, 'Saudi Arabia is one of Lunit's key strategic markets for the expansion of medical AI in the Middle East.'
▲The Ministry of Health and Welfare announced on the 13th that it has selected an additional 31 local governments to participate in the 2025 2nd integrated support pilot project for medical care, nursing, and care. With this, a total of 131 local governments will participate in the pilot project. This project aims to integrate the provision of medical, nursing, and care services by local governments so that elderly individuals and people with disabilities who experience difficulties in daily life continue to live in their communities, ahead of the nationwide implementation of the Law on Integrated Support for Local Care (Care Integrated Support Act) in March next year.
▲The artificial intelligence (AI) company specializing in diagnosing and treating brain diseases, Neurophet, announced that it will participate in the 2025 Bio International Convention (Bio USA) held in Boston, USA, from the 16th to the 19th (local time). The company will showcase its software 'Neurophet AQUA AD,' which can monitor the therapeutic effects and side effects of dementia treatments. The company will set up a booth in the Korean pavilion.
▲The drug development corporation Shaperon announced that it will participate in Bio USA to discuss strategic partnerships and expansion of joint projects with over 30 global pharmaceutical companies based on the non-clinical and global clinical results of its core pipelines, including treatments for COVID-19 pneumonia, atopic dermatitis, and diabetic foot ulcers.
▲The drug development corporation OliX Pharmaceuticals announced plans to seek collaboration opportunities with global companies through strategic partnering meetings during Bio USA. The company previously signed partnership agreements with Eli Lilly and the L'Oréal Group.
▲SK bioscience announced on the 13th that it was selected as an excellent organization for the biological safety management of livestock infectious disease pathogens at the '2025 Korean Biosafety Conference' and received a commendation from the head of the Animal and Plant Quarantine Agency. The company was recognized for establishing its own biosafety system and thoroughly implementing related laws and regulations, including the 'Livestock Infectious Disease Prevention Act.'
▲Huons Meditech participated in the World Health Expo Miami 2025 held in Miami, Florida, from the 11th to the 13th (local time). The company showcased its skin drug delivery device 'Derma Shine Pro' and the extracorporeal shockwave lithotripsy device 'ASADAL-M1,' highlighting its technological capabilities and product competitiveness.
▲Yonsei University Yongin Severance Hospital announced on the 12th that it signed a memorandum of understanding (MOU) with East Avenue Medical Center in the Philippines to build a digital innovation hospital and promote patient exchange. EAMC is a national general hospital with a capacity of 1,000 beds under the Philippine Department of Health. Yongin Severance Hospital plans to provide consulting for the introduction of optimized technologies within the hospital system based on its successful experience in operating 5G-based smart hospital technologies, artificial intelligence (AI), and the Internet of Medical Things (IoMT) solutions. They will also work on establishing a cooperative system for high-level treatments, specialized consultations, and providing second opinions.
▲Korea University Medical Center reported on the 13th that KMI Korea Medical Institute has donated 100 million won. KMI Director Lee Kwang-bae said, 'I decided to make the donation because I believe that the values of life respect and the healthy life of humanity match the direction of both Korea University Medical Center and KMI, which is committed to the healthy life of citizens,' adding, 'We will continue our social contribution activities in the future.'
▲Professor Kim Hyo-jin from Inje University Busan Paik Hospital has been inaugurated as the president of the Korean Society of Medical Mycology. The term is for two years starting from June 7, 2025. The Korean Society of Medical Mycology was established in March 1994 to promote the field of medical mycology and the efficient management of mycotic diseases.
▲Kwangdong Pharmaceutical has launched a scar management medical device called 'Kwangdong Derma Touch Ultra Plus.' This gel-type medical device is used for managing and protecting thickened or protruding scars and healed wounds. It can be used on various areas such as acne scars, surgical marks, and old wounds. It is available for purchase at pharmacies without a prescription and is sold in units of 12g.
▲Dongkook Pharmaceutical announced the release of the Max Special Set to celebrate the sixth anniversary of the launch of the 'Expert Madeca Melacapture Ampoule' from the cosmetics brand Centellian24. This high-concentration premium ampoule helps improve blemishes, spots, freckles, and pigmentation, and the product set includes the brand's first new product 'Capsule Cream.'
▲The Korean Medical Association and Boryung have signed a business alliance agreement to provide prompt and effective medical support in the event of a disaster. Both organizations agreed to jointly provide medical support not only in preparation for disasters but also in various volunteer activities.
▲The Korean Pharmaceutical and Bio Association's AI New Drug Convergence Research Institute is recruiting participants for the 'LAIDD AI New Drug Development Mentoring Project,' a practical training program for AI drug development, until the 18th. The target audience includes employees of pharmaceutical and bio companies, AI developers, and university (graduate school) students and job seekers related to AI drug development. After a subject-specific basic competency test and interviews, 50 participants will be selected, with 10 per mentor, and free online and offline training and team projects will be conducted from next month to October.